Document is current

Article History

First Online: 12 May 2017

Competing interests

: The authors declare that M.W. has received research grants from Acceleron, Actelion, Bayer, Isarna, Merck Sharp & Dohme, Merck EMD (Emanuel Merck, Darmstadt), Novocure, Piqur and Roche and honoraria for lectures, advisory board participation or consulting from Bristol-Myers Squibb, Celldex, Immunocellular Therapeutics, Isarna, Magforce, Merck Sharp & Dohme, Merck EMD, Northwest Biotherapeutics, Novocure, Pfizer, Roche, Teva and Tocagen. M. Preusser has received research support from Böhringer-Ingelheim, GlaxoSmithKline, Merck Sharp & Dohme and Roche, as well as honoraria for lectures, advisory board participation or consulting from Bristol-Myers Squibb, CMC Contrast, Gerson Lehrman Group, GlaxoSmithKline, Mundipharma, Novartis and Roche. D.A.R. has received research grants from Celldex Therapeutics, Incyte and Midatech, as well as honoraria for lectures, advisory board participation or consulting from Abbvie, Amgen, Bristol-Myers Squibb, Cavion, Celldex Therapeutics, EMD Serono, Genentech (Roche), Inovio, Juno Pharmaceuticals, Merck & Co, Midatech, Momenta Pharmaceuticals, Novartis, Novocure, Oxigene, Regeneron, and Stemline Therapeutics. M. Platten has received research support from Merck and Novartis, as well as honoraria for lectures, consultation or advisory board participation from Alexion, Bayer, Genentech (Roche), Merck & Co, Medac, Miltenyi Biotec, Novartis and Teva. M. Platten also holds patents on isocitrate dehydrogenase vaccines and aryl hydrocarbon receptor inhibition. P.R. has received research support from Merck Sharp & Dohme and honoraria for lectures or advisory board participation from Merck Sharp & Dohme, Molecular Partners, Novartis and Roche. W.W. has received research funding from Apogenix, Böhringer-Ingelheim, Genentech (Roche), Merck Sharp & Dohme and Pfizer, as well as honoraria for participating in a speaker's bureau for Merck Sharp & Dohme and consulting for Genentech (Roche). J.H.S. declares that he is an employee of Annias, a shareholder in Annias and Istari, and has received honoraria for consulting from Celldex, BrainLAB and Medicenna, as well as licensing fees from Celldex.